December 10, 2018

FDA Approves Biosimilar to Neulasta for Myelosuppressive Chemotherapy

By Kristen Coppock, MA, Editor
Published Online: Tuesday, Nov 06, 2018

Officials with the FDA have approved Coherus BioSciences’ Udenyca™ (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy.1,2 The drug is  a biosimilar to Amgen’s Neulasta (pegfilgrastim).1

Udenyca is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Udenyca is the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC), according the Coherus.2

The FDA’s approval of Udenyca was supported by a comprehensive analytical similarity package, as well as pharmacokinetic, pharmacodynamic and immunogenicity studies, including more than 600 healthy subjects.2

“Udenyca’s robust clinical package includes a dedicated immunogenicity similarity study in over 300 healthy subjects,” said Barbara Finck, MD, Chief Medical Officer of Coherus BioSciences, in a prepared statement.2 “In support of that study, and as part of our commitment to ensuring patient safety, we deployed a battery of sensitive immunogenicity assays. This effort not only supported the biosimilarity of Udenyca, but also advanced the understanding of the immunogenic response of pegfilgrastim products.”

The most common adverse reactions (≥ 5% difference in incidence compared to placebo) reported by patients using Udenyca were bone pain and pain in extremity.2 According to Coherus, patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors, such as pegfilgrastim or filgrastim products, should not use Udenyca.2

The drug is Coherus’ first to receive an approval from the FDA or the EC, which approved Udenyca on September 21, 2018. In a statement, Chris Thompson, Senior Vice President of Sales for Coherus, said company officials believe the oncology marketplace is ideal for biosimilars for a number of reasons, and they remain committed to vigorously launching products in that space.2

“Our oncology-focused, highly capable and fully-staffed commercial team is in place. We are confident that our U.S.-based manufacturing network has the finished goods in inventory to meet our highest expected demand for an extended period,” said Thompson, in his statement.2

Furthermore, Denny Lanfear, Chairman, CEO and President of Coherus Biosciences, said company officials believe that competition is essential in controlling price increases, and that Udenyca will play an important role in curbing those increases when the product is launched.2

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us